Analysis of Sputum Culture and Drug Sensitivity Test in Patients with Severe Pneumonia Who Have Abnormal Klebsiella Pneumoniae
European Journal of Clinical and Biomedical Sciences
Volume 6, Issue 2, April 2020, Pages: 22-25
Received: Apr. 20, 2020; Accepted: May 6, 2020; Published: May 19, 2020
Views 28      Downloads 19
Authors
Yanru Luo, Department of Pharmacy, The First Affiliated Hospital of Jinan University, Guangzhou, China
Jufeng Li, Department of Pharmacy, The First Affiliated Hospital of Jinan University, Guangzhou, China
Xuwei Lin, ICU, Peking University Shenzhen Hospital, Shenzhen, China
Lingfeng Zeng, Department of Pharmacy, The First Affiliated Hospital of Jinan University, Guangzhou, China
Jieyi Zhou, Department of Pharmacy, The First Affiliated Hospital of Jinan University, Guangzhou, China
Zhidong Zhang, Department of Pharmacy, The First Affiliated Hospital of Jinan University, Guangzhou, China
Article Tools
Follow on us
Abstract
Objective: To analyze sputum culture and drug sensitivity test in patients with severe pneumonia who have abnormal Klebsiella pneumoniae. Methods: 216 patients who were diagnosed as severe pneumonia were invested to join our study. All participants received the sputum culture test before they receive the treatment, their inspection time was from January 2016 to December 2016. we use different antibiotic discs to test the drug resistance in test medium, it can test the effects of several major antibiotics on Klebsiella pneumoniae. Our research is focus on the information about Drug resistance for Klebsiella pneumoniae. The collection information includes patient characteristics, Klebsiella pneumoniae source medical department and drug resistance of different antibiotics for Klebsiella pneumoniae. Result: Most Klebsiella pneumoniae sample from ICU (29.6%), Respiratory ward (31.0%), Neurological ward (19.0%) and Cardiovascular ward (43.7%). The klebsiella pneumoniae sample of another source are less than 5% in our research result. Some antibiotics have good influence to Klebsiella pneumoniae, that include cefoperazone/sulbactam, Meropenem and Ciprofloxacin (8.9% & 10.9% & 12.9%). However, the result indicate the Aztreonam has strong drug resistance for Klebsiella pneumoniae, it has 66 out of 99 (66.66%) number of resistant. Conclusion: The cefoperazone/sulbactam, Meropenem and Ciprofloxacin have good influence to improve klebsiella pneumoniae situation on patients with severe pneumonia. Additionally, some medical departments have more patients who severe pneumonia caused by klebsiella pneumoniae, such as ICU, Respiratory ward, Neurological ward and Cardiovascular ward.
Keywords
Drug Resistance, Sputum Culture, Severe Pneumonia
To cite this article
Yanru Luo, Jufeng Li, Xuwei Lin, Lingfeng Zeng, Jieyi Zhou, Zhidong Zhang, Analysis of Sputum Culture and Drug Sensitivity Test in Patients with Severe Pneumonia Who Have Abnormal Klebsiella Pneumoniae, European Journal of Clinical and Biomedical Sciences. Vol. 6, No. 2, 2020, pp. 22-25. doi: 10.11648/j.ejcbs.20200602.12
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Teramoto S, Yoshida K, Hizawa N. Update on the pathogenesis and management of pneumonia in the elderly-roles of aspiration pneumonia. RespirInvestig. 2015; 53 (5): 178-84.
[2]
Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44: S27–72.
[3]
Allewelt M, Schüler P, Bolcskei PL, Mauch H, Lode H. Pneumonia SGoA. Ampicillin sulbactam vs clindamycin/cephalosporin for the treatment of aspiration pneumonia and primary lung abscess. Clin Microbiol Infect. 2016; 10 (2): 163-170.
[4]
Kadowaki M, Demura Y, Mizuno S, Uesaka D, Ameshima S, Miyamori I, et al. Reappraisal of clindamycin IV monotherapy for treatment of mild-to-moderate aspiration pneumonia in elderly patients. Chest. 2015; 127 (4): 1276-1282.
[5]
Ott SR, Allewelt M, Lorenz J, Reimnitz P, Lode H, Group GLAS. Moxifloxacin vsampicillin/sulbactam in aspiration pneumonia and primary lung abscess. Infection. 2018; 36 (1): 23-30.
[6]
Barckow D, Schwigon CD. Cefepime versus cefotaxime in the treatment oflower respiratory tract infections. J Antimicrob Chemother. 1993; 32: 187-193.
[7]
Kochanowski K, Morinishi L, Altschuler SJ, Wu LF. Drug persistence–from antibiotics to cancer therapies, Curr. Opin. Syst. Biol. 2018; 10: 1–8.
[8]
Volm M, Efferth T. Prediction of cancer drug resistance and implications for personalized medicine, Front. Oncol. 2015; 5: 282.
[9]
Nielsen BS, Balslev E, Poulsen TS, Nielsen D, Møller T, Mortensen CE, Holmstrøm K. miR-21 expression in cancer cells may not predict resistance to adjuvant trastuzumab in primary breast cancer. Front. Oncol. 2016; 4: 207.
[10]
Munoz-Price ls, Poirel l, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases, Lancet Infect. Dis. 2017; 13 (9): 785–796.
[11]
Pitout JD, Nordmann P, Poirel L. Carbapenemase-Producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance, Antimicrob. Agents Chemother. 2015; 59 (10): 5873–5884.
[12]
Navon-Venezia S, Kondratyeva K, Caratolli A. Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance. FEMS Mic Rev. 2017; 41 (3): 252–75.
[13]
Moradigaravand D, Martin V, Peacock SJ, Parkhill J. Evolution and epidemiology of multidrug-resistant Klebsiella pneumoniae in the United Kingdom and Ireland. mBio. 2017; 8 (1): 1976-1916.
[14]
Montgomerie JZ. Epidemiology of Klebsiella and hospital-associated infections. Rev Infect Dis 1979; 1 (5): 736–53.
[15]
Melot B, Colot J, Guerrier G. Bacteremic community-acquired infections due to Klebsiella pneumoniae: clinical and microbiological presentation in New Caledonia, 2008–2013. Int J Infect Dis 2015; 41: 29–31.
[16]
Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, et al. Implementing an antibiotic stewardship program: guidelines by the In- fectious Diseases Society of America and the Society for Healthcare Epidemi- ology of America. Clin Infect Dis 2016; 44: 51–77.
[17]
Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic pre- scribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ. 2016; 340: 2096.
[18]
Baggs J, Fridkin SK, Pollack LA, Srinivasan A, Jernigan JA. Estimating national trends in inpatient antibiotic use among US hospitals from 2006 to 2012. JAMA Intern Med 2016; 176: 1639–48.
[19]
US Centers for Disease Control and Prevention. Antimicrobial Use and Resis- tance (AUR) Module. Atlanta, GA: CDC; 2017.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186